Alexandria Real Estate Equities, Inc. Announces Significant Early Renewal With insitro for a 6-Year Lease Extension at the Alexandria Center for Advanced Technologies Mega Campus in South San Francisco

Rhea-AI Summary

Alexandria Real Estate Equities, Inc. announces insitro's 6-year lease extension for laboratory space at the Alexandria Center for Advanced Technologies in South San Francisco. This renewal highlights insitro's commitment to AI-driven drug discovery and development, emphasizing the importance of specialized laboratory space for AI-enhanced R&D in life sciences.

Insights

Real Estate Investment Analyst

The extension of insitro's lease at the Alexandria Center for Advanced Technologies in South San Francisco signifies a robust demand for specialized life science real estate in prime innovation clusters. This deal not only reaffirms Alexandria Real Estate Equities' strategic positioning within a key market but also reflects the growing trend of life sciences companies investing heavily in infrastructure that supports AI and ML-driven research. The early renewal, spanning six years, indicates a stable and potentially expanding revenue stream for Alexandria, which is beneficial for the company's financial health and attractiveness to investors.

Given the dense concentration of life science companies in the area, Alexandria's nearly 3.4 million RSF operational footprint as of December 31, 2023, demonstrates a strong market presence. The integration of amenities aimed at attracting top talent further enhances the value proposition of Alexandria's properties, which could lead to increased demand and higher rental rates over time. This strategic move may have positive implications for the company's stock performance, as investors typically favor real estate firms with strong tenant commitments and the ability to create ecosystems that foster tenant growth.

Biotechnology Industry Analyst

The partnership between Alexandria Real Estate Equities and insitro underscores the critical role of advanced R&D infrastructure in the biotechnology sector. AI and ML are increasingly becoming integral to drug discovery and development, necessitating significant investments in lab space equipped to handle the computational and data requirements of these technologies. insitro's commitment through 2034 reflects confidence in the long-term viability of its AI-powered drug discovery platform.

insitro's focus on diseases like liver disease, cancer and ALS, combined with its AI and ML expertise, positions it to potentially disrupt traditional R&D models by accelerating the discovery of biomarkers and genetic drivers of disease. This could lead to a faster pipeline of novel therapies, benefiting patients and stakeholders in the healthcare sector. The collaboration between real estate and biotech companies highlights the symbiotic relationship that can accelerate innovation and potentially lead to increased investment in biotech firms that leverage AI and ML effectively.

PASADENA, Calif., April 1, 2024 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative life science mega campuses in AAA innovation cluster locations, today announced that insitro, a leading machine learning-powered drug discovery and development company, has executed an early renewal for a 6-year lease extension through August 31, 2034 for 143,188 RSF at 279 East Grand Avenue on the Alexandria Center^® for Advanced Technologies – South San Francisco mega campus in the San Francisco Bay Area. In 2018, recognizing the potential of insitro's innovative platform that leverages artificial intelligence (AI), and specifically machine learning (ML), and data at scale to decode complex biology and discover new medicines in therapeutic areas such as metabolism, oncology and neuroscience, Alexandria executed its first lease with insitro for nearly 36,000 RSF of Labspace^® infrastructure at 279 East Grand Avenue. The significant early renewal of insitro's headquarters and R&D site underscores the drug discovery and development company's long-term commitment to the Alexandria Center for Advanced Technologies – South San Francisco mega campus. It also highlights the need for laboratory space to generate the large datasets that power AI capabilities in the discovery and development of new medicines and affirms that Alexandria is strongly positioned to enable companies working in the growing area of AI-enhanced laboratory-based research and development.

AI/ML hold immense potential to make the discovery and development of new medicines faster and more efficient, ultimately reducing the time and cost involved in the overall R&D process — including the discovery of new biology, the development of novel therapies and the design of clinical trials. AI's power is derived from the application of computational approaches to high-quality data at scale. The complexity and volume of data needed to train AI models involve highly integrated R&D infrastructure and drive the need for specialized technical laboratory space in Alexandria's core life science markets. With its goal of bringing better medicines faster to the patients who can benefit most through ML and data at scale, insitro is creating computational models of disease from massive laboratory-generated datasets and aggregated human cohort data to discover new biomarkers and genetic drivers of disease that anchor an advancing pipeline of therapeutics in liver disease, cancer and ALS (amyotrophic lateral sclerosis).

Alexandria entered South San Francisco, the birthplace of biotechnology, in 1998, and today the submarket is home to the densest concentration of life science companies in the San Francisco Bay Area. Over the past 25 years, Alexandria has strategically assembled a well-located footprint in South San Francisco, consisting of nearly 3.4 million RSF in operation as of December 31, 2023. The Alexandria Center for Advanced Technologies – South San Francisco mega campus, which aggregates 1.0 million RSF of operating properties and future development opportunities as of December 31, 2023, is at the heart of the submarket and is positioned to foster the growth of disruptive companies, like insitro. As part of Alexandria's purposeful efforts to enable its tenants to recruit and retain the brightest talent to advance their mission-critical science, the company is envisioning an elevated and activated ecosystem through the seamless integration of collaborative amenities into this mega campus, including a high-tech conference center, an inviting café and lounge, experiential walking paths promoting health and wellness, and enhanced connectivity to adjacent transportation hubs.

About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500^® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche since our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative life science mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland and Research Triangle. Alexandria has a total market capitalization of $33.1 billion and an asset base in North America of 73.5 million SF as of December 31, 2023, which includes 42.0 million RSF of operating properties, 5.5 million RSF of Class A/A+ properties undergoing construction and one near-term project expected to commence construction in the next two years, 2.1 million RSF of priority anticipated development and redevelopment projects and 23.9 million SF of future development projects. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in life science mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns and greater long-term asset value. For more information on Alexandria, please visit www.are.com.

Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding the impact of Alexandria's facilities on the advancement of medicines and treatments. These forward-looking statements are based on Alexandria's present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q.

CONTACT: Joel S. Marcus, Executive Chairman & Founder, (626) 578-9693, jmarcus@are.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-announces-significant-early-renewal-with-insitro-for-a-6-year-lease-extension-at-the-alexandria-center-for-advanced-technologies-mega-campus-in-south-san-francisco-302103996.html

SOURCE Alexandria Real Estate Equities, Inc.

FAQ

What is the significance of insitro's lease extension at the Alexandria Center for Advanced Technologies?

The lease extension underscores insitro's dedication to AI-powered drug discovery and the need for specialized laboratory space for advanced research and development.

What areas does insitro focus on in drug discovery?

Insitro concentrates on metabolism, oncology, and neuroscience to develop new medicines using AI and machine learning.

Where is the Alexandria Center for Advanced Technologies located?

The mega campus is situated in South San Francisco, known for its dense concentration of life science companies.

What amenities does Alexandria plan to integrate into the mega campus?

Alexandria aims to include a high-tech conference center, a café, wellness paths, and enhanced connectivity to transportation hubs for its tenants.